Loading
An early Seattle trial that gave people with melanoma that had spread their own T cells grown to recognise tyrosinase, a melanoma protein. It started in 1995 and the registry lists it as completed in 2006.
The registry's official title is a phase I study of cellular adoptive immunotherapy using genetically modified and unmodified autologous CD8+ tyrosinase-specific T cells for patients with metastatic melanoma; the record lists it as phase 1/2, started in October 1995 and completed in March 2006, with an estimated enrolment of 20 (ClinicalTrials.gov NCT00002786). Cassian Yee is listed as study chair, the sponsor is Fred Hutchinson Cancer Center with the National Cancer Institute as collaborator, and the interventions are aldesleukin and therapeutic T cells (ClinicalTrials.gov NCT00002786). No results are posted.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, National Cancer Institute (NIH).
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Shares Endogenous T-cell therapy, Fred Hutchinson Cancer Center, Cassian Yee, Melanoma.
Shares Endogenous T-cell therapy, Aldesleukin (high-dose IL-2), Fred Hutchinson Cancer Center, Cassian Yee.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/